Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Trelegy Ellipta
Pharma
Theravance sells remaining Trelegy royalties to GSK for $225M
Theravance estimates that its lifetime earnings from GSK's inhaler Trelegy total $1.52 billion.
Zoey Becker
Jun 2, 2025 9:18am
AZ's Breztri set up for label expansion with 2 asthma trial wins
May 2, 2025 11:30am
AbbVie's Rinvoq tops TV drug ad spenders' list
Jun 6, 2023 9:15am
AbbVie continues top TV drug ad spender reign
Oct 10, 2022 10:57am
GSK, E&I report finds dissatisfaction with asthma management
Sep 9, 2022 7:30am
AstraZeneca's Breztri puts a '60s spin on an animated theme
Feb 28, 2022 8:25am
